Safety of tirofiban in acute ischemic stroke: The SaTIS trial

Stroke

Volumn 42, Issue 9, 2011, Pages 2388-2392

  Siebler, Mario ^a   Hennerici, Michael G ^b   Schneider, Dietmar ^c   Von Reutern, Gerhard M ^d   Seitz, Rüdiger J ^a   Röther, Joachim ^e   Witte, Otto W ^f   Hamann, Gerhard ^g   Junghans, Ulrich ^h   Villringer, Arno ⁱ   Fiebach, Jochen B ^j  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Asclepios Hospital Nidda   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g HSK Kliniken GmbH   (Germany)

^h SANA KLINIKUM OFFENBACH   (Germany)

ⁱ MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

acute ischemic stroke; cerebral hemorrhage; mortality; platelets; tirofiban

Indexed keywords

PLACEBO; TIROFIBAN;

ACUTE DISEASE; ADULT; AGED; AORTA DISSECTION; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MORTALITY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE; UROGENITAL TRACT BLEEDING; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STROKE; TIME FACTORS; TYROSINE;

EID: 80052392748     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.599662     Document Type: Article

References (27)

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet. 2004;363:768-774.
2. Bluhmki E, Chamorro A, Davalos A, Maching T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 H after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomized controlled trial. Lancet Neurol. 2009;8:1095-1102.
3. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orogogozo JM; ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial. Lancet. 2006;368:1871-1878.
4. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, et al. AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
5. Nordt TK, Moser M, Kohler B, Ruef J, Peter K, Kübler W, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haemost. 1998;80:881-886.
6. Qureshi AI, Siddiqui AM, Kim SH, Hanel RA, Xavier AR, Kirmani JF, et al. Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Roentgenol. 2004; 25:322-328.
7. Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102:1301-1310.
8. Yang Y, Li Q, Nakada MT, Yang T, Shuaib A. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats. J Neurosurg. 2001;94:582-588.
9. Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des. 2004;10:1567-1576.
10. Zhang L, Zhang ZG, Zhang R, Morris D, Lu M, Coller BS, et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation. 2003;107: 2837-2843.
11. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
12. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, et al. CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (ACC/AHA guidelines) initiative. Circulation. 2006;114: 1380-1387.
13. Junghans U, Siebler M. Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Circulation. 2003;107:2717-2721.
14. van Dellen D, Tiivas CA, Jarvi K, Marschall C, Higman DJ, Imray CH. Transcransial Doppler ultrasonography-directed intravenous glycoprotein IIb/IIIa receptor antagonist therapy to control transient cerebral microemboli before and after carotid endarterectomy. Br J Surg. 2008;95: 709-713.
15. Junghans U, Seitz R, Ritzl A, Wittsack HJ, Fink GR, Freund HJ, et al. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban. Neurology. 2002;58:476-478.
16. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, et al. Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:529-535.
17. Quershi AL, Hussain MS, Nasar A, Kirmani JF, Divani AA, Ahmed S, et al. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIb/IIIa receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19:371-373.
18. Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis. 2001;12:308-312.
19. Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
20. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850-1856.
21. Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, et al. TARGET Investigators. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation. 2002; 105:2730-2736.
22. Molina CA. Monitoring and imaging the clot during systemic thrombolysis in stroke patients. Expert Rev Cardiovasc Ther. 2007;5: 91-98.
23. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330.
24. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke. 2004;35: 705-709.
25. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, Ewing JR, et al. Analysis of combined treatment of embolic stroke in rat with rtPA and GPIIb/IIIa inhibitor. J Cereb Blood Flow Metab. 2005;25:87-97.
26. Eckert B, Koch C, Thomalla G, Roether J, Zeumer H. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator. Report of 3 cases. Stroke. 2002;33: 1424-1427.
27. Ries T, Siemonsen S, Grzyska U, Zeumer H, Fiehler J. Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke. 2009;40:1750-1757